Adaptations of the IGF system during malignancy: human skeletal muscle versus the systemic environment.
Presented in this study are data derived from a unique cohort of patients both with and without cancer, for whom we not only have serum samples, allowing us to investigate systemic factors impacting on skeletal muscle maintenance, but also primary skeletal muscle cultures giving us a model to mimic the in vivo muscle milieu. Possible local effects of autocrine/paracrine and endocrine IGF system components impacting on myoblast growth and differentiation could therefore be assessed. We report for the first time that the decrease in myoblast stem cell numbers seen with normal aging is lost in cancer patients. We further report that serum IGF-I, IGF-II and IGFBP-3 all show positive correlations with myoblast retrieval in control patients, but that with the exception of IGFBP-3 these correlations are lost in malignancy. Indeed IGF-II switches to a negative correlation with myotube formation in malignancy. Furthermore we provide initial evidence to suggest that there is an apparent altered regulation of local IGFBP-3 production during malignancy which may enable satellite cell proliferation, stem cell infiltration or both. Finally we show the importance of investigations not only monitoring the systemic impact of serum factors on skeletal muscle responses but also critically assessing the role that locally produced muscle IGFBP-3 may have on the systemic environment.
Foulstone
E J
EJ
Division of Surgery, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, England. foulstone@bristol.ac.uk
Savage
P B
PB
Crown
A L
AL
Holly
J M
JM
Stewart
C E
CE
D000328:Adult; D000367:Age Factors; D000368:Aged; D001835:Body Weight; D002478:Cells, Cultured; D003402:Creatine Kinase / Q000097:blood; D017558:Elective Surgical Procedures; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000473:pathology*; D005831:Genital Diseases, Female / Q000473:pathology; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000473:pathology / Q000503:physiopathology*; D032446:Myoblasts / Q000473:pathology; D009369:Neoplasms / Q000503:physiopathology*; D011863:Radioimmunoassay
D018972:Insulin-Like Growth Factor Binding Protein 3; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D003402:Creatine Kinase